Reflections on the Use of MAOIs

November 1, 2006

Jonathan Cole, MD Professor of Psychiatry, Harvard Medical School, Senior Consultant, McLean Hospital Dr. Cole has disclosed that he has no consultant, speaking, or grant support relationships with any commercial companies pertaining to this educational activity. He has disclosed that he owns stock in both Pfizer and Bristol-Myers Squibb. Dr. Cole has disclosed that psychostimulants and oral selegiline have not been approved by the U.S. Food and Drug Administration for use in the treatment of depression. Please consult product labeling for the approved uses. Dr. Carlat has reviewed the content of the interview and has determined that there is no commercial bias present.

Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)
Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
READ MORE

General Psychiatry
Using SAMe In Clinical Practice with Garrett Rossi, MD
Read More

General Psychiatry
Psychopharm Commandment #6: MAOIs
MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.
Listen now